Davies A Case-Based Guide to Clinical Endocrinology

1. Auflage 2008
ISBN: 978-1-60327-103-5
Verlag: Humana Press
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 504 Seiten

Reihe: Contemporary Endocrinology

In this thought-provoking book, distinguished clinicians provide stimulating instruction and insights into a wide variety of endocrine subjects, teaching readers modern management of the conditions described and offering targeted entry into the literature. The text reflects much of the curriculum for clinical endocrine training recommended by the Association of Program Directors in Clinical Endocrinology. Concise cases are followed by multiple choice questions to enhance learning.

Autoren/Hrsg.

Davies, Terry F.

Inhaltsverzeichnis

1;Preface;6
1.1;References;7
2;Contents;8
3;Contributors;16
4;Part I The Pituitary Gland;24
4.1;Introduction;25
4.1.1;Physiology;25
4.1.2;Disorders of the Pituitary Gland;26
4.1.3;Other Etiologies of Sellar Masses;27
4.1.4;Hypopituitarism;28
4.1.5;Suggested Readings;29
4.2;Pituitary Apoplexy;31
4.2.1;Objectives;31
4.2.2;Case Presentation;31
4.2.3;How the DiagnosisWas Made;34
4.2.4;Lessons Learned;34
4.2.5;References;38
4.2.6;Multiple-Choice Questions;38
4.3;When and How to Stop Cabergoline Treatment in Microprolactinomas;41
4.3.1;Case Presentation;42
4.3.2;Lessons Learned;44
4.3.3;Conclusion;46
4.3.4;References;46
4.3.5;Questions;47
4.4;Cushing’s Disease;49
4.4.1;Objectives;49
4.4.2;Case Presentation;49
4.4.3;How the DiagnosisWas Made;51
4.4.4;Lessons Learned;54
4.4.5;Suggested Readings;54
4.4.6;Multiple-Choice Questions;55
5;Part II Thyroid Overactivity;57
5.1;Introduction;59
5.2;Amiodarone-Induced Hyperthyroidism;63
5.2.1;Objectives;63
5.2.2;Case Presentation;63
5.2.3;Background;64
5.2.4;Amiodarone-Induced Thyrotoxicosis;65
5.2.5;Type 2;66
5.2.6;Diagnosis;66
5.2.7;Treatment;66
5.2.8;How the DiagnosisWas Made;67
5.2.9;Lessons Learned;67
5.2.10;References;68
5.2.11;Multiple-Choice Questions;69
5.3;Interferon-Induced Hyperthyroidism;71
5.3.1;Objectives;71
5.3.2;Case Presentation;71
5.3.3;Background;72
5.3.4;How the DiagnosisWas Made;77
5.3.5;Lessons Learned;78
5.3.6;References;79
5.3.7;Multiple-Choice Questions;80
5.4;Subclinical Hyperthyroidism Due to a Multinodular Thyroid;83
5.4.1;Objectives;83
5.4.2;Case Presentation;83
5.4.3;Background;84
5.4.4;How the DiagnosisWas Made;85
5.4.5;Lessons Learned;86
5.4.6;References;86
5.4.7;Multiple-Choice Questions;87
5.5;Subacute (De Quervain’s) Thyroiditis;89
5.5.1;Objectives;89
5.5.2;Case Presentation;89
5.5.3;Background;90
5.5.4;How the DiagnosisWas Made;91
5.5.5;Lessons Learned;92
5.5.6;References;92
5.5.7;Multiple-Choice Questions;93
6;Part III Thyroid Underactivity;95
6.1;Introduction;97
6.1.1;Physiology;97
6.1.2;Pathophysiology;97
6.1.3;Treatment;98
6.1.4;References;98
6.2;Amiodarone-Induced Hypothyroidism;99
6.2.1;Objectives;99
6.2.2;Case Presentation;99
6.2.3;How the DiagnosisWas Made;100
6.2.4;Lessons Learned;101
6.2.5;References;104
6.2.6;Questions;104
6.3;Autoimmune Hypothyroidism with Persistent Elevation of TSH;107
6.3.1;Objectives;107
6.3.2;Case Presentation;107
6.3.3;How the DiagnosisWas Made;109
6.3.4;Lessons Learned;112
6.3.5;References;112
6.3.6;Questions;112
6.4;Hashimoto’s Thyroiditis and Type 1 Diabetes;115
6.4.1;Objectives;115
6.4.2;Case Presentation;115
6.4.3;How the DiagnosisWas Made;116
6.4.4;Lessons Learned;117
6.4.5;References;120
6.4.6;Questions;120
7;Part IV Thyroid Cancer;123
7.1;Introduction;124
7.1.1;References;128
7.2;Papillary Thyroid Cancer;131
7.2.1;Objectives;131
7.2.2;Case Presentation;131
7.2.3;Risk Factors for Thyroid Cancer;132
7.2.4;Well-Differentiated Thyroid Cancer;132
7.2.5;Risk Factors in Thyroid Cancer for Recurrence and Mortality;133
7.2.6;Surgical Recommendations for Thyroid Cancer;133
7.2.7;Remnant Ablation for Thyroid Cancer;134
7.2.8;Hormone Suppressive Therapy in Thyroid Cancer;136
7.2.9;Long-Term Follow-up and Surveillance for Thyroid Cancer;137
7.2.10;References;138
7.2.11;Multiple-Choice Questions;140
7.3;Metastatic Papillary Thyroid Cancer;143
7.3.1;Objectives;143
7.3.2;Case Presentation;143
7.3.3;How the DiagnosisWas Made;144
7.3.4;Lessons Learned;144
7.3.5;References;146
7.3.6;Multiple-Choice Questions (3–5);146
7.4;Medullary Thyroid Cancer;149
7.4.1;Objectives;149
7.4.2;Case Presentation;149
7.4.3;Overview of Medullary Thyroid Cancer;150
7.4.4;How the DiagnosisWas Made;152
7.4.5;Lessons Learned;153
7.4.6;ret;153
7.4.7;References;158
7.4.8;Multiple-Choice Questions;158
7.5;Follicular Thyroid Carcinoma with Pulmonary and Osseous Metastases;161
7.5.1;Objectives;161
7.5.2;Case Presentation;161
7.5.3;Lessons Learned;164
7.5.4;Our Approach;171
7.5.5;References;172
7.5.6;Multiple-Choice Questions;173
8;Part V Adrenal;175
8.1;Adrenal Insufficiency;177
8.1.1;Objectives;177
8.1.2;Case Presentation;177
8.1.3;How the DiagnosisWas Made;178
8.1.4;Lessons Learned;178
8.2;Cushing’s Syndrome;181
8.2.1;Objective;181
8.2.2;Case Presentation;181
8.2.3;How the DiagnosisWas Made?;182
8.2.4;Lessons Learned;182
8.3;An Incidentally Discovered Adrenal Mass;185
8.3.1;Objective;185
8.3.2;Case Presentation;185
8.3.3;How the DiagnosisWas Made?;186
8.3.4;Lessons Learned;186
9;Part VI Hyperparathyroidism;189
9.1;Introduction;191
9.1.1;Pathophysiology of Hyperparathyroidism;192
9.1.2;Clinical Features of Primary Hyperparathyroidism;193
9.1.3;Differential Diagnosis and Investigation;194
9.1.4;Management of Acute Hypercalcemia (see Case 19);196
9.1.5;Management of Primary Hyperparathyroidism;196
9.1.6;References;198
9.2;Differentiation of Primary Hyperparathyroidism for Familial Benign Hypocalciuric Hypercalcemia;201
9.2.1;Case Presentation;201
9.2.2;How the DiagnosisWas Made;202
9.2.3;Diagnosis;202
9.2.4;Lessons Learned;203
9.2.5;Suggested Readings;203
9.2.6;Multiple-Choice Questions;203
9.3;Management and Investigation of Acute Hypercalcemia;205
9.3.1;Case Presentation;205
9.3.2;Diagnosis;206
9.3.3;How the DiagnosisWas Made;206
9.3.4;Lessons Learned;207
9.3.5;Suggested Readings;207
9.3.6;Questions;207
9.4;Evaluation of Complex Primary Hyperparathyroidism;209
9.4.1;Case Presentation;209
9.4.2;How the DiagnosisWas Made;210
9.4.3;Lessons Learned;211
9.4.4;References;211
9.4.5;Suggested Readings;211
9.4.6;Multiple-Choice Questions;211
9.5;Evaluation of Hypercalcemia in Infancy;213
9.5.1;Case Presentation;213
9.5.2;How the DiagnosisWas Made;214
9.5.3;Lessons Learned;214
9.5.4;Suggested Readings;215
9.5.5;Multiple-Choice Questions;215
10;Part VII Metabolic Bone Diseases;217
10.1;Introduction;219
10.1.1;References;223
10.2;Osteoporosis Due to Hormonal Withdrawal: Common Mistakes;225
10.2.1;Objectives;225
10.2.2;Case Presentation;225
10.2.3;How the DiagnosisWas Made;227
10.2.4;Lessons Learned;228
10.2.5;References;229
10.2.6;Questions;229
10.3;Osteomalacia: A Cause of Bisphosphonate Failure;231
10.3.1;Objectives;231
10.3.2;Case Presentation;231
10.3.3;How the DiagnosisWas Made;232
10.3.4;Lessons Learned;233
10.3.5;References;235
10.3.6;Questions;235
10.4;Unusual Manifestations of Paget’s Disease of Bone;237
10.4.1;Objectives;237
10.4.2;Case Presentation;237
10.4.3;How the DiagnosisWas Made;238
10.4.4;Lessons Learned;240
10.4.5;Suggested Readings;243
10.4.6;Questions;243
10.5;Solid Organ Transplantation, Chronic Renal Impairment, and Skeletal Complications;245
10.5.1;Objectives;245
10.5.2;Case Presentation;245
10.5.3;How the DiagnosisWas Made;246
10.5.4;Lessons Learned;248
10.5.5;References;249
10.5.6;Questions;250
11;Part VIII Endocrine Disorders of Males;251
11.1;Introduction;253
11.2;Congenital Isolated Hypogonadotropic Hypogonadism;255
11.2.1;Objectives;255
11.2.2;Case Presentation;255
11.2.3;How the DiagnosisWas Made;256
11.2.4;Lessons Learned;256
11.2.5;References;260
11.2.6;Multiple-Choice Questions;261
11.3;Klinefelter Syndrome;263
11.3.1;Objectives;263
11.3.2;Case Presentation;263
11.3.3;How the DiagnosisWas Made;264
11.3.4;Lessons Learned;265
11.3.5;Treatment;270
11.3.6;References;271
11.3.7;Multiple-Choice Questions;272
11.4;Low Testosterone in Obesity and Type 2 Diabetes;275
11.4.1;Objectives;275
11.4.2;Case Presentation;275
11.4.3;How the DiagnosisWas Made;276
11.4.4;Lessons Learned;276
11.4.5;Suggested Readings;280
11.4.6;Multiple-Choice Questions;280
12;Part IX Female Reproduction;283
12.1;Introduction;285
12.1.1;Physiology of the Reproductive System;285
12.1.2;Menstrual Dysfunction;287
12.1.3;Diagnostic Approach to Menstrual Cycle Disorders;291
12.1.4;Suggested Readings;292
12.2;Central Hypogonadism;295
12.2.1;Objective;295
12.2.2;Case Presentation;295
12.2.3;How the DiagnosisWas Made;297
12.2.4;Lessons Learned;298
12.2.5;Multiple-Choice Questions;298
12.3;Premature Ovarian Failure;301
12.3.1;Objective;301
12.3.2;Case Presentation;301
12.3.3;How the DiagnosisWas Made;302
12.3.4;Lessons Learned;304
12.3.5;Multiple-Choice Questions;305
12.4;Oligomenorrhea and Hyperandrogenemia;307
12.4.1;Objective;307
12.4.2;Case Presentation;307
12.4.3;How the DiagnosisWas Made;309
12.4.4;Lessons Learned;312
12.4.5;Multiple-Choice Questions;312
13;Part X Pregnancy;315
13.1;Introduction;317
13.1.1;References;319
13.2;Hypertension in Pregnancy and Women with Child- Bearing Potential;321
13.2.1;Objectives;321
13.2.2;Case Presentation;321
13.2.3;Background;321
13.2.4;Lessons Learned;325
13.2.5;References;326
13.3;Hashimoto’s Hypothyroidism During Pregnancy;327
13.3.1;Objectives;327
13.3.2;Case Presentation;327
13.3.3;Normal Thyroid Physiology During Pregnancy;328
13.3.4;LT4 Dosage Requirements During Pregnancy;329
13.3.5;Maternal and Fetal Complications of Inadequate Maternal LT4 Therapy;329
13.3.6;Lessons Learned;330
13.3.7;References;330
13.4;Type I Diabetes Mellitus During Pregnancy;331
13.4.1;Objectives;331
13.4.2;Case Presentation;331
13.4.3;Physiology of Type 1 Diabetes Mellitus During Pregnancy;333
13.4.4;Lessons Learned;336
13.4.5;References;336
13.4.6;Questions;336
14;Part XI Type 1 Diabetes;341
14.1;Introduction;343
14.1.1;Epidemiology;343
14.1.2;Genetic Etiology;343
14.1.3;Etiologic Factors;345
14.1.4;Pathogenesis;346
14.1.5;Diagnostic Criteria;346
14.1.6;Classification of Diabetes;347
14.1.7;Future Directions;347
14.1.8;References;348
14.2;Type 1 Diabetes Onset with Ketoacidosis and Suspected Cerebral Edema;349
14.2.1;Case Presentation;350
14.2.2;How the DiagnosisWas Made;350
14.2.3;Discussion;351
14.2.4;Lesson Learned;352
14.2.5;References;352
14.3;En Passant Diagnosis of Type 1 Diabetes in Infancy;353
14.3.1;Objectives;353
14.3.2;Case Presentation;354
14.3.3;How the DiagnosisWas Made;355
14.3.4;Discussion;355
14.3.5;Lesson Learned;356
14.3.6;References;356
14.3.7;Multiple-Choice Questions;356
14.4;Type 1 Diabetes and Comorbidity of Addison’s Disease;359
14.4.1;Objectives;359
14.4.2;Case Presentation;360
14.4.3;How the DiagnosisWas Made;360
14.4.4;Discussion;361
14.4.5;Lesson Learned;361
14.4.6;References;361
14.4.7;Multiple-Choice Questions;362
15;Part XII Type 2 Diabetes;363
15.1;Introduction;365
15.1.1;References;366
15.2;Exenatide in Type 2 Diabetes: Indications and Initiation;369
15.2.1;Objective;369
15.2.2;Case Presentation;369
15.2.3;How the DiagnosisWas Made;370
15.2.4;Lessons Learned;371
15.2.5;References;373
15.2.6;Multiple-Choice Questions;374
15.3;Insulin Therapy in the Management of Diabetes Mellitus Type 2;375
15.3.1;Objective;375
15.3.2;Case Presentation;375
15.3.3;How the DiagnosisWas Made;376
15.3.4;Lessons Learned;376
15.3.5;Suggested Readings;379
15.3.6;Multiple-Choice Questions;379
15.4;Treatment of Type 2 Diabetes Mellitus with Oral Agents;381
15.4.1;Objective;381
15.4.2;Case Presentation;381
15.4.3;How the DiagnosisWas Made;382
15.4.4;Lessons Learned;382
15.4.5;References;387
15.4.6;Multiple-Choice Questions;387
16;Part XIII Lipid Abnormalities;389
16.1;Introduction;391
16.2;Combination Drug Therapy in a Case of Severe Hypercholesterolemia;393
16.2.1;Objectives;393
16.2.2;Case Presentation;393
16.2.3;How the DiagnosisWas Made;395
16.2.4;Lessons Learned;396
16.2.5;References;399
16.2.6;Multiple-Choice Questions;399
16.3;A Young Man with Abdominal Pain and Very High Triglycerides: The Chylomicronemia Syndrome;401
16.3.1;Objective;401
16.3.2;Case Presentation;401
16.3.3;Clinical and Laboratory Characteristics of Chylomicronemia Syndrome;402
16.3.4;Physiology of Triglyceride-Rich Particles;403
16.3.5;Etiology of Chylomicronemia Syndrome;403
16.3.6;Primary (Genetic) Causes of Hypertriglyceridemia;404
16.3.7;Secondary (Acquired) Causes of Hypertriglyceridemia;404
16.3.8;Management of Chylomicronemia Syndrome;405
16.3.9;Suggested Readings;406
16.3.10;Multiple-Choice Questions;406
16.4;Roughly Equivalent Lipids in a Middle-Aged Obese Man at Risk for Coronary Disease;409
16.4.1;Objectives;409
16.4.2;Case Presentation;409
16.4.3;How the DiagnosisWas Made;410
16.4.4;Lessons Learned;411
16.4.5;Suggested Readings;412
16.4.6;Multiple-Choice Questions;412
17;Part XIV Obesity and the Metabolic Syndrome;415
17.1;Introduction;417
17.1.1;Epidemic of Obesity;417
17.1.2;Endocrine Control of the Energy Balance System;417
17.1.3;The Present and Future of Obesity Management;418
17.1.4;Suggested Readings;419
17.2;Metabolic Syndrome;421
17.2.1;Objectives;421
17.2.2;Case Presentation;421
17.2.3;How the DiagnosisWas Made;422
17.2.4;Lessons Learned;425
17.2.5;References;425
17.2.6;Multiple-Choice Questions;426
17.3;Polycystic Ovarian Syndrome;429
17.3.1;Objectives;429
17.3.2;Case Presentation;429
17.3.3;How the DiagnosisWas Made;430
17.3.4;Treatment;432
17.3.5;Long-Term Complications;434
17.3.6;Lessons Learned;434
17.3.7;Suggested Readings;435
17.3.8;Multiple-Choice Questions;435
17.4;Bariatric Surgery;439
17.4.1;Objectives;439
17.4.2;Case Presentation;439
17.4.3;How the DiagnosisWas Made;440
17.4.4;Lessons Learned;444
17.4.5;References;444
17.4.6;Multiple-Choice Questions;444
18;Part XV Puberty;447
18.1;Introduction;449
18.1.1;Central Precocious Puberty;450
18.1.2;Delayed Puberty;451
18.1.3;References;453
18.1.4;Suggested Readings;453
18.2;Amenorrhea;455
18.2.1;Objectives;455
18.2.2;Case Presentation;455
18.2.3;How the DiagnosisWas Made;456
18.2.4;References;457
18.2.5;Multiple-Choice Questions;457
18.3;Early Puberty and Hyperthyroidism;459
18.3.1;Objectives;459
18.3.2;Case Presentation;459
18.3.3;How the DiagnosisWas Made;460
18.3.4;References;462
18.3.5;Multiple-Choice Questions;463
18.4;Hypothalamic Hamartoma;467
18.4.1;Objectives;467
18.4.2;Case Presentation;467
18.4.3;Diagnostic Test Results;468
18.4.4;Description;469
18.4.5;Diagnosis;469
18.4.6;Differential Diagnosis;469
18.4.7;How the DiagnosisWas Made;469
18.4.8;Treatment;471
18.4.9;Suggested Readings;471
18.4.10;Multiple-Choice Questions;472
18.5;Leydig Cell Adenoma;475
18.5.1;Objective;475
18.5.2;Case Presentation;475
18.5.3;Diagnostic Test Results;476
18.5.4;Diagnosis;477
18.5.5;Differential Diagnosis;477
18.5.6;How the DiagnosisWas Made;477
18.5.7;Suggested Readings;478
18.5.8;Multiple-Choice Questions;478
18.6;Prolactinoma;481
18.6.1;Objective;481
18.6.2;Case Presentation;481
18.6.3;Diagnostic Test Results;482
18.6.4;Diagnosis;483
18.6.5;Differential Diagnosis;483
18.6.6;How the DiagnosisWas Made;483
18.6.7;Suggested Readings;485
18.6.8;Multiple-Choice Questions;485
18.7;Turner Syndrome;487
18.7.1;Objectives;487
18.7.2;Case Presentation;487
18.7.3;Differential Diagnosis of Primary Amenorrhea;488
18.7.4;The Hypogonadism of Turner Syndrome;489
18.7.5;Suggested Readings;490
18.7.6;Multiple-Choice Questions;490
19;Part XVI Instructive Rarities;493
19.1;Introduction;495
19.2;Hypothalamic Damage and Obesity;497
19.2.1;Objectives;497
19.2.2;Case Presentation;497
19.2.3;How the DiagnosisWas Made;499
19.2.4;Lessons Learned;499
19.2.5;References;502
19.2.6;Multiple-Choice Questions;503
19.3;Systemic Mastocytosis;505
19.3.1;Objectives;505
19.3.2;Case Presentation;505
19.3.3;How the DiagnosisWas Made;506
19.3.4;Lessons Learned;506
19.3.5;References;507
19.3.6;Multiple-Choice Questions;508
19.4;Testosteronoma;511
19.4.1;Objectives;511
19.4.2;Case Presentation;511
19.4.3;How the DiagnosisWas Made;512
19.4.4;Laboratory and Diagnostic Investigations;514
19.4.5;Lessons Learned;517
19.4.6;References;517
19.4.7;Multiple-Choice Questions;517
20;Index;521